Postes actifs de Gad Shani
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Thulium Ltd.
 Thulium Ltd. Medical SpecialtiesHealth Technology Thulium Therapy is developing a new radioactive source for Brachytherapy, a cancer treatment modality were a radiation source is inserted into the tumor. The isotope, Thulium 170 (Tm170), is a radioactive variant of the stable metal Tm169. Although the concept of Brachytherapy is not new, much room remains for improvement in order to maximize the probability of completely eliminating a localized tumor while minimizing the radiation damage to the surrounding healthy tissue. | Directeur Technique/Scientifique/R&D | 12/07/2009 | - |
| Fondateur | 21/04/2010 | - | |
| Ben-Gurion University of the Negev | Corporate Officer/Principal | - | - |
Historique de carrière de Gad Shani
Statistiques
Internationale
| Israël | 3 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Thulium Ltd.
Thulium Ltd. Medical SpecialtiesHealth Technology Thulium Therapy is developing a new radioactive source for Brachytherapy, a cancer treatment modality were a radiation source is inserted into the tumor. The isotope, Thulium 170 (Tm170), is a radioactive variant of the stable metal Tm169. Although the concept of Brachytherapy is not new, much room remains for improvement in order to maximize the probability of completely eliminating a localized tumor while minimizing the radiation damage to the surrounding healthy tissue. | Health Technology |
